Literature DB >> 29377378

Evaluation of a Multimodal, Direct-to-Patient Educational Intervention Targeting Barriers to Osteoporosis Care: A Randomized Clinical Trial.

Maria I Danila1, Ryan C Outman1, Elizabeth J Rahn1, Amy S Mudano1, David T Redden1, Peng Li1, Jeroan J Allison2, Fred A Anderson2, Allison Wyman2, Susan L Greenspan3, Andrea Z LaCroix4,5, Jeri W Nieves6, Stuart L Silverman7, Ethel S Siris8, Nelson B Watts9, Michael J Miller10, Jeffrey R Curtis1, Amy H Warriner1, Nicole C Wright1, Kenneth G Saag1.   

Abstract

Osteoporosis treatment rates are declining, even among those with past fractures. Novel, low-cost approaches are needed to improve osteoporosis care. We conducted a parallel group, controlled, randomized clinical trial evaluating a behavioral intervention for improving osteoporosis medication use. A total of 2684 women with self-reported fracture history after age 45 years not using osteoporosis therapy from US Global Longitudinal Study of Osteoporosis in Women (GLOW) sites were randomized 1:1 to receive a multimodal, tailored, direct-to-patient, video intervention versus usual care. The primary study outcome was self-report of osteoporosis medication use at 6 months. Other outcomes included calcium and vitamin D supplementation, bone mineral density (BMD) testing, readiness for behavioral change, and barriers to treatment. In intent-to-treat analyses, there were no significant differences between groups (intervention versus control) in osteoporosis medication use (11.7% versus 11.4%, p = 0.8), calcium supplementation (31.8% versus 32.6%, p = 0.7), vitamin D intake (41.3% versus 41.9%, p = 0.8), or BMD testing (61.8% versus 57.1%, p = 0.2). In the intervention group, fewer women were in the precontemplative stage of behavior change, more women reported seeing their primary care provider, had concerns regarding osteonecrosis of the jaw, and difficulty in taking/remembering to take osteoporosis medications. We found differences in BMD testing among the subgroup of women with no prior osteoporosis treatment, those who provided contact information, and those with no past BMD testing. In per protocol analyses, women with appreciable exposure to the online intervention (n = 257) were more likely to start nonbisphosphonates (odds ratio [OR] = 2.70; 95% confidence interval [CI] 1.26-5.79) compared with the usual care group. Although our intervention did not increase the use of osteoporosis therapy at 6 months, it increased nonbisphosphonate medication use and BMD testing in select subgroups, shifted participants' readiness for behavior change, and altered perceptions of barriers to osteoporosis treatment. Achieving changes in osteoporosis care using patient activation approaches alone is challenging.
© 2018 American Society for Bone and Mineral Research. © 2018 American Society for Bone and Mineral Research.

Entities:  

Keywords:  BEHAVIORAL INTERVENTION; BISPHOSPHONATES; FRACTURE PREVENTION; NONBISPHOSPHONATES; OSTEOPOROSIS

Mesh:

Substances:

Year:  2018        PMID: 29377378      PMCID: PMC6016546          DOI: 10.1002/jbmr.3395

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  72 in total

1.  Evaluation of primary nonadherence to oral bisphosphonate therapy.

Authors:  Keri N Hogan; Jessica L Milchak; Rachel M F Heilmann; Sarah J Billups; Thomas Delate
Journal:  J Am Geriatr Soc       Date:  2013-11       Impact factor: 5.562

2.  Underdiagnosis and Undertreatment of Osteoporosis: The Battle to Be Won.

Authors:  Paul D Miller
Journal:  J Clin Endocrinol Metab       Date:  2016-02-24       Impact factor: 5.958

Review 3.  Stage theories of health behavior: conceptual and methodological issues.

Authors:  N D Weinstein; A J Rothman; S R Sutton
Journal:  Health Psychol       Date:  1998-05       Impact factor: 4.267

4.  Effect of self-referral on bone mineral density testing and osteoporosis treatment.

Authors:  Amy H Warriner; Ryan C Outman; Adrianne C Feldstein; Douglas W Roblin; Jeroan J Allison; Jeffrey R Curtis; David T Redden; Mary M Rix; Brandi E Robinson; Ana G Rosales; Monika M Safford; Kenneth G Saag
Journal:  Med Care       Date:  2014-08       Impact factor: 2.983

5.  Design and baseline characteristics of the osteoporotic fractures in men (MrOS) study--a large observational study of the determinants of fracture in older men.

Authors:  Eric Orwoll; Janet Babich Blank; Elizabeth Barrett-Connor; Jane Cauley; Steven Cummings; Kristine Ensrud; Cora Lewis; Peggy M Cawthon; Robert Marcus; Lynn M Marshall; Joan McGowan; Kathy Phipps; Sherry Sherman; Marcia L Stefanick; Katie Stone
Journal:  Contemp Clin Trials       Date:  2005-10       Impact factor: 2.226

6.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Authors:  Dennis M Black; Pierre D Delmas; Richard Eastell; Ian R Reid; Steven Boonen; Jane A Cauley; Felicia Cosman; Péter Lakatos; Ping Chung Leung; Zulema Man; Carlos Mautalen; Peter Mesenbrink; Huilin Hu; John Caminis; Karen Tong; Theresa Rosario-Jansen; Joel Krasnow; Trisha F Hue; Deborah Sellmeyer; Erik Fink Eriksen; Steven R Cummings
Journal:  N Engl J Med       Date:  2007-05-03       Impact factor: 91.245

7.  A randomized trial of direct-to-patient communication to enhance adherence to beta-blocker therapy following myocardial infarction.

Authors:  David H Smith; Judith M Kramer; Nancy Perrin; Richard Platt; Douglas W Roblin; Kimberly Lane; Michael Goodman; Winnie W Nelson; Xiuhai Yang; Stephen B Soumerai
Journal:  Arch Intern Med       Date:  2008-03-10

8.  A randomized trial of a mailed intervention and self-scheduling to improve osteoporosis screening in postmenopausal women.

Authors:  Amy H Warriner; Ryan C Outman; Elizabeth Kitchin; Lang Chen; Sarah Morgan; Kenneth G Saag; Jeffrey R Curtis
Journal:  J Bone Miner Res       Date:  2012-12       Impact factor: 6.741

9.  Effects of individualized bone density feedback and educational interventions on osteoporosis knowledge and self-efficacy: a 12-yr prospective study.

Authors:  Feitong Wu; Laura L Laslett; Karen Wills; Brian Oldenburg; Graeme Jones; Tania Winzenberg
Journal:  J Clin Densitom       Date:  2014-09-11       Impact factor: 2.617

10.  The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design.

Authors:  F H Hooven; J D Adachi; S Adami; S Boonen; J Compston; C Cooper; P Delmas; A Diez-Perez; S Gehlbach; S L Greenspan; A LaCroix; R Lindsay; J C Netelenbos; J Pfeilschifter; C Roux; K G Saag; P Sambrook; S Silverman; E Siris; N B Watts; F A Anderson
Journal:  Osteoporos Int       Date:  2009-05-26       Impact factor: 4.507

View more
  15 in total

Review 1.  Supporting patients to get the best from their osteoporosis treatment: a rapid realist review of what works, for whom, and in what circumstance.

Authors:  Z Paskins; O Babatunde; A Sturrock; L S Toh; R Horne; I Maidment
Journal:  Osteoporos Int       Date:  2022-06-11       Impact factor: 5.071

2.  Understanding Physicians' Perceptions of Patient-Identified Barriers to Osteoporosis Medication Initiation: A Cognitive Mapping Approach.

Authors:  Haiyan Qu; Stuart L Silverman; Richard M Shewchuk; Jeffrey R Curtis; Shamly Austin; Susan L Greenspan; Jeri W Nieves; Ryan C Outman; Amy H Warriner; Nelson B Watts; Kenneth G Saag
Journal:  Risk Manag Healthc Policy       Date:  2022-07-05

Review 3.  Quality Measures and Quality Improvement Initiatives in Osteoporosis-an Update.

Authors:  S French; S Choden; Gabriela Schmajuk
Journal:  Curr Osteoporos Rep       Date:  2019-12       Impact factor: 5.096

4.  At Odds About the Odds: Women's Choices to Accept Osteoporosis Medications Do Not Closely Agree with Physician-Set Treatment Thresholds.

Authors:  Emma O Billington; A Lynn Feasel; Gregory A Kline
Journal:  J Gen Intern Med       Date:  2019-10-17       Impact factor: 5.128

5.  Factors associated with the contemplative stage of readiness to initiate osteoporosis treatment.

Authors:  G Adami; K G Saag; A S Mudano; E J Rahn; N C Wright; R C Outman; S L Greenspan; A Z LaCroix; J W Nieves; S L Silverman; E S Siris; N B Watts; M J Miller; S Ladores; J R Curtis; M I Danila
Journal:  Osteoporos Int       Date:  2020-02-04       Impact factor: 4.507

Review 6.  Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS.

Authors:  Athanasios D Anastasilakis; Jessica Pepe; Nicola Napoli; Andrea Palermo; Christos Magopoulos; Aliya A Khan; M Carola Zillikens; Jean-Jacques Body
Journal:  J Clin Endocrinol Metab       Date:  2022-04-19       Impact factor: 6.134

Review 7.  Vitamin D Deficiency and Oral Health: A Comprehensive Review.

Authors:  João Botelho; Vanessa Machado; Luís Proença; Ana Sintra Delgado; José João Mendes
Journal:  Nutrients       Date:  2020-05-19       Impact factor: 5.717

Review 8.  Interventions to improve adherence to anti-osteoporosis medications: an updated systematic review.

Authors:  D Cornelissen; S de Kunder; L Si; J-Y Reginster; S Evers; A Boonen; M Hiligsmann
Journal:  Osteoporos Int       Date:  2020-05-01       Impact factor: 4.507

Review 9.  Medication-Related Osteonecrosis of the Jaw (MRONJ): Are Antiresorptive Drugs the Main Culprits or Only Accomplices? The Triggering Role of Vitamin D Deficiency.

Authors:  Luca Dalle Carbonare; Monica Mottes; Maria Teresa Valenti
Journal:  Nutrients       Date:  2021-02-08       Impact factor: 5.717

10.  Use of path modeling to inform a clinical decision support application to encourage osteoporosis medication use.

Authors:  Michael J Miller; Tzuchen Jou; Maria I Danila; Amy S Mudano; Elizabeth J Rahn; Ryan C Outman; Kenneth G Saag
Journal:  Res Social Adm Pharm       Date:  2020-09-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.